• Je něco špatně v tomto záznamu ?

Prognostic Value of EGFR Exon-20 Insertions in Czech Patients With Advanced Non-small Cell Lung Cancer

J. Skrickova, M. Pesek, P. Opalka, L. Koubkova, M. Zemanova, M. Hrnciarik, J. Blazek, M. Svaton, J. Krejci, H. Coupkova, D. Dolezal, T. Tuzova, L. Holubec, P. Mahadevia, K. Sandstrom, P. Kunovszki, M. Barinova, K. Hurdalkova, O. Fischer, M....

. 2021 ; 41 (11) : 5625-5634. [pub] -

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22003267

BACKGROUND/AIM: Per literature, patients with epidermal growth factor receptor (EGFR) exon-20 insertions respond poorly to tyrosine kinase inhibitors (TKIs). This study analyzed real-world data to examine the prognostic and predictive value of these mutations. PATIENTS AND METHODS: We conducted a retrospective cohort study using Czech TULUNG Registry data, with data on multiple mutation types, collected in 2011-2020. RESULTS: We analyzed 554 (95.85%) patients with EGFR exon-19 deletions or exon-21 L858R substitutions and 24 (4.15%) patients with exon-20 insertions who received first-line high-value therapies. We summarized clinical characteristics and outcomes in all patients and by cohort. The risk of progression was statistically significantly higher (86%) in the exon-20 insertion cohort compared to the cohort with other mutations. Although not statistically significant, the risk of death was 44% higher in patients with exon-20 insertions. CONCLUSION: Advanced NSCLC patients with rare EGFR exon-20 insertions have a high risk of progression.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003267
003      
CZ-PrNML
005      
20220127150516.0
007      
ta
008      
220113s2021 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/anticanres.15378 $2 doi
035    __
$a (PubMed)34732435
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Skrickova, Jana $u Department of Pulmonary Diseases and Tuberculosis, University Hospital Brno, Brno, Czech Republic
245    10
$a Prognostic Value of EGFR Exon-20 Insertions in Czech Patients With Advanced Non-small Cell Lung Cancer / $c J. Skrickova, M. Pesek, P. Opalka, L. Koubkova, M. Zemanova, M. Hrnciarik, J. Blazek, M. Svaton, J. Krejci, H. Coupkova, D. Dolezal, T. Tuzova, L. Holubec, P. Mahadevia, K. Sandstrom, P. Kunovszki, M. Barinova, K. Hurdalkova, O. Fischer, M. Cernovska, M. Bratova
520    9_
$a BACKGROUND/AIM: Per literature, patients with epidermal growth factor receptor (EGFR) exon-20 insertions respond poorly to tyrosine kinase inhibitors (TKIs). This study analyzed real-world data to examine the prognostic and predictive value of these mutations. PATIENTS AND METHODS: We conducted a retrospective cohort study using Czech TULUNG Registry data, with data on multiple mutation types, collected in 2011-2020. RESULTS: We analyzed 554 (95.85%) patients with EGFR exon-19 deletions or exon-21 L858R substitutions and 24 (4.15%) patients with exon-20 insertions who received first-line high-value therapies. We summarized clinical characteristics and outcomes in all patients and by cohort. The risk of progression was statistically significantly higher (86%) in the exon-20 insertion cohort compared to the cohort with other mutations. Although not statistically significant, the risk of death was 44% higher in patients with exon-20 insertions. CONCLUSION: Advanced NSCLC patients with rare EGFR exon-20 insertions have a high risk of progression.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protinádorové látky $x terapeutické užití $7 D000970
650    _2
$a nemalobuněčný karcinom plic $x farmakoterapie $x genetika $x mortalita $x patologie $7 D002289
650    _2
$a progrese nemoci $7 D018450
650    _2
$a chemorezistence $7 D019008
650    _2
$a erbB receptory $x genetika $7 D066246
650    _2
$a exony $7 D005091
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a genetická predispozice k nemoci $7 D020022
650    _2
$a lidé $7 D006801
650    _2
$a nádory plic $x farmakoterapie $x genetika $x mortalita $x patologie $7 D008175
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a inzerční mutageneze $7 D016254
650    _2
$a fenotyp $7 D010641
650    _2
$a inhibitory proteinkinas $x terapeutické užití $7 D047428
650    _2
$a registrace $7 D012042
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
651    _2
$a Česká republika $7 D018153
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pesek, Milos $u Department of Pneumology, University Hospital Pilsen, Pilsen, Czech Republic
700    1_
$a Opalka, Petr $u Clinic of Pneumology, Bulovka Hospital, Prague, Czech Republic
700    1_
$a Koubkova, Leona $u Department of Pneumology, Motol University Hospital, Prague, Czech Republic
700    1_
$a Zemanova, Milada $u Department of Oncology, General University Hospital in Prague, Prague, Czech Republic $u First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
700    1_
$a Hrnciarik, Michal $u Department of Pneumology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic $u Faculty of Medicine, Charles University in Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Blazek, Jiri $u Department of Pneumology, University Hospital Pilsen, Pilsen, Czech Republic
700    1_
$a Svaton, Martin $u Department of Pneumology, University Hospital Pilsen, Pilsen, Czech Republic
700    1_
$a Krejci, Jana $u Clinic of Pneumology, Bulovka Hospital, Prague, Czech Republic
700    1_
$a Coupkova, Helena $u Clinic of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Dolezal, Daniel $u Department of Pneumology, Masaryk Hospital Usti nad Labem, Usti nad Labem, Czech Republic
700    1_
$a Tuzova, Tana $u Department of Oncology, Hospital Jihlava, Jihlava, Czech Republic
700    1_
$a Holubec, Lubos $u Department of Clinical Oncology, Na Homolce Hospital, Prague, Czech Republic
700    1_
$a Mahadevia, Parthiv $u Janssen Global Medical Affairs, Raritan, NJ, U.S.A
700    1_
$a Sandstrom, Kristina $u Janssen Global Services, Stockholm, Sweden
700    1_
$a Kunovszki, Peter $u Janssen Global Services, Budapest, Hungary; pkunovsz@its.jnj.com
700    1_
$a Barinova, Magda $u Institute of Biostatistics and Analyses Ltd., Brno, Czech Republic
700    1_
$a Hurdalkova, Karolina $u Institute of Biostatistics and Analyses Ltd., Brno, Czech Republic
700    1_
$a Fischer, Ondrej $u Department of Pulmonary Diseases and Tuberculosis, University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Cernovska, Marketa $u Department of Pneumology, University Hospital Pilsen, Pilsen, Czech Republic
700    1_
$a Bratova, Monika $u Department of Pulmonary Diseases and Tuberculosis, University Hospital Brno, Brno, Czech Republic
773    0_
$w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 41, č. 11 (2021), s. 5625-5634
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34732435 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127150512 $b ABA008
999    __
$a ok $b bmc $g 1750891 $s 1154416
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 41 $c 11 $d 5625-5634 $e - $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Možnosti archivace